Shanghai IASO Biotechnology
Main focus: Gene editing for the treatment of cancer
Company stage: Clinical
Diseases: T- and B-cell malignancies
Genome editing tool: CRISPR-Cas9
Funding stage: Private
Location: Shanghai and Nanjing, China
Website: http://www.iasobio.com/
Pipeline: http://www.iasobio.com/proline.php
Shanghai IASO Biotechnology develops next generation allogeneic CAR-T cell therapies and uses CRISPR to make the CAR-T cells fratricide-resistent. The company is currently developing multiple pre-clinical programmes using CRISPR, to treat T- and B-cell malignancies.